首页> Annals of oncology : official journal of the European Society for Medical Oncology> Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.

Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.

导出 OA

翻译打印收藏纠错

第一作者： E L,Rosenthal

第一单位： Department of Surgery, University of Alabama at Birmingham, Birmingham elr@stanford.edu.

作者： E L,Rosenthal ^[1] ; T K,Chung ^[2] ; W B,Parker ^[3] ; P W,Allan ^[4] ; L,Clemons ^[2] ; D,Lowman ^[2] ; J,Hong ^[5] ; F R,Hunt ^[3] ; J,Richman ^[2] ; R M,Conry ^[6] ; K,Mannion ^[7] ; W R,Carroll ^[2] ; L,Nabell ^[6] ; E J,Sorscher ^[3]

作者单位： Department of Surgery, University of Alabama at Birmingham, Birmingham elr@stanford.edu. ^[1] Department of Surgery, University of Alabama at Birmingham, Birmingham. ^[2] PNP Therapeutics, Inc., Birmingham. ^[3] Southern Research Institute, Birmingham. ^[4] Department of Cellular, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham. ^[5] Department of Medicine, University of Alabama at Birmingham, Birmingham. ^[6] Department of Otolaryngology Head and Neck Surgery, Vanderbilt University, Nashville, USA. ^[7]

关键词 fludarabine gene therapy human clinical trial purine nucleoside phosphorylase